WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe
暂无分享,去创建一个
P. C. de Witt Hamer | D. Noske | T. Würdinger | C. Van Noorden | Philip C De Witt Hamer | Cornelis J F Van Noorden | Shahryar E Mir | David Noske | Tom Würdinger | S. E. Mir | C. van Noorden | Shahryar E. Mir
[1] P. Russell,et al. Cell cycle regulation of human WEE1. , 1995, The EMBO journal.
[2] Tsuyoshi Arai,et al. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents , 2009, Molecular Cancer Therapeutics.
[3] J. Janetka,et al. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. , 2008, Expert opinion on investigational drugs.
[4] Daniel F Ortwine,et al. 4-Phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-dione inhibitors of the checkpoint kinase Wee1. Structure-activity relationships for chromophore modification and phenyl ring substitution. , 2006, Journal of medicinal chemistry.
[5] M. Gonen,et al. Phase I trial of the cyclin-dependent kinase inhibitor and protein kinase C inhibitor 7-hydroxystaurosporine in combination with Fluorouracil in patients with advanced solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] C. Hudis,et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] H. Koga,et al. Cell cycle regulation by the Wee1 Inhibitor PD0166285, Pyrido [2,3-d] pyimidine, in the B16 mouse melanoma cell line , 2006, BMC Cancer.
[8] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[9] Daniela S Krause,et al. Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.
[10] E. Sausville,et al. Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Yamaguchi,et al. Control Mechanism of the Circadian Clock for Timing of Cell Division in Vivo , 2003, Science.
[12] M. Yanagida,et al. HIV-1 Vpr induces cell cycle G2 arrest in fission yeast (Schizosaccharomyces pombe) through a pathway involving regulatory and catalytic subunits of PP2A and acting on both Wee1 and Cdc25. , 2001, Virology.
[13] Z. Szallasi,et al. A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.
[14] S. Davidson,et al. A phase I and pharmacokinetic study of short infusions of UCN-01 in patients with refractory solid tumors. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[15] Paul Russell,et al. Negative regulation of mitosis by wee1 +, a gene encoding a protein kinase homolog , 1987, Cell.
[16] H. Hirai,et al. MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil , 2010, Cancer biology & therapy.
[17] P. Nurse,et al. Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation , 1997, The EMBO journal.
[18] T. Lawrence,et al. Wild-Type TP53 Inhibits G2-Phase Checkpoint Abrogation and Radiosensitization Induced by PD0166285, a WEE1 Kinase Inhibitor , 2002, Radiation research.
[19] E. Small,et al. Time to disease progression to evaluate a novel protein kinase C inhibitor, UCN‐01, in renal cell carcinoma , 2004, Cancer.
[20] Tak-Hong Cheung,et al. Transcriptional repression of WEE1 by Kruppel-like factor 2 is involved in DNA damage-induced apoptosis , 2005, Oncogene.
[21] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[22] Y. Wang,et al. Binding of 14-3-3beta to the carboxyl terminus of Wee1 increases Wee1 stability, kinase activity, and G2-M cell population. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[23] A. Kumagai,et al. Positive regulation of Wee1 by Chk1 and 14-3-3 proteins. , 2001, Molecular biology of the cell.
[24] A. Doherty,et al. In vitro pharmacological characterization of PD 166285, a new nanomolar potent and broadly active protein tyrosine kinase inhibitor. , 1997, The Journal of pharmacology and experimental therapeutics.
[25] W. Denny,et al. Synthesis and structure-activity relationships of N-6 substituted analogues of 9-hydroxy-4-phenylpyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of Wee1 and Chk1 checkpoint kinases. , 2008, European journal of medicinal chemistry.
[26] S. Kornbluth,et al. Cdc25 and Wee1: analogous opposites? , 2007, Cell Division.
[27] T. Chou,et al. 90-kDa Heat Shock Protein Inhibition Abrogates the Topoisomerase I Poison-Induced G2/M Checkpoint in p53-Null Tumor Cells by Depleting Chk1 and Wee1 , 2009, Molecular Pharmacology.
[28] P. C. de Witt Hamer. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. , 2010, Neuro-oncology.
[29] J. Sebolt-Leopold,et al. Knockdown of Chk1, Wee1 and Myt1 by RNA Interference Abrogates G2 Checkpoint and Induces Apoptosis , 2004, Cancer biology & therapy.
[30] E. Baker,et al. Structure and inhibition of the human cell cycle checkpoint kinase, Wee1A kinase: an atypical tyrosine kinase with a key role in CDK1 regulation. , 2005, Structure.
[31] Guido Kroemer,et al. Cell death by mitotic catastrophe: a molecular definition , 2004, Oncogene.
[32] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[33] R. Medema,et al. Human prostate epithelium lacks Wee1A-mediated DNA damage-induced checkpoint enforcement , 2007, Proceedings of the National Academy of Sciences.
[34] P. Richardson,et al. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose‐escalation study , 2010, British journal of haematology.
[35] Thomas Dandekar,et al. Explorative data analysis of MCL reveals gene expression networks implicated in survival and prognosis supported by explorative CGH analysis , 2008, BMC Cancer.
[36] W. Denny,et al. Structure-activity relationships for 2-anilino-6-phenylpyrido[2,3-d]pyrimidin-7(8H)-ones as inhibitors of the cellular checkpoint kinase Wee1. , 2005, Bioorganic & medicinal chemistry letters.
[37] S. Ramalingam,et al. A Phase I Study of 17-Allylamino-17-Demethoxygeldanamycin Combined with Paclitaxel in Patients with Advanced Solid Malignancies , 2008, Clinical Cancer Research.
[38] Valerie Cavett,et al. Activation Domain-dependent Degradation of Somatic Wee1 Kinase* , 2009, The Journal of Biological Chemistry.
[39] L. Neckers,et al. Hsp90 phosphorylation, Wee1 and the cell cycle , 2010, Cell cycle.
[40] H. Kuwano,et al. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[41] J. Aten,et al. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. , 2010, Cancer cell.
[42] F. McKeon,et al. Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmically activated cdc2 kinase , 1993, Cell.
[43] Rong Li,et al. Mitotic progression becomes irreversible in prometaphase and collapses when Wee1 and Cdc25 are inhibited , 2011, Molecular biology of the cell.
[44] Pierre Dubus,et al. Cdk1 is sufficient to drive the mammalian cell cycle , 2007, Nature.
[45] T. Dougherty,et al. Anti-Angiogenic Activity of Selected Receptor Tyrosine Kinase Inhibitors, PD166285 and PD173074: Implications for Combination Treatment with Photodynamic Therapy , 2004, Investigational New Drugs.
[46] U. Mansmann,et al. Differential gene expression in colon carcinoma cells and tissues detected with a cDNA array , 1999, International journal of cancer.
[47] A. Maitra,et al. MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts , 2011, Clinical Cancer Research.
[48] H. Hirai,et al. Discovery of gene expression-based pharmacodynamic biomarker for a p53 context-specific anti-tumor drug Wee1 inhibitor , 2009, Molecular Cancer.
[49] Jun Yu Li,et al. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator. , 2001, Cancer research.
[50] Yoshiaki Miyauchi,et al. Cyclins and cyclin‐dependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis , 2003, Hepatology.
[51] T. Tsuruo,et al. Akt/Protein Kinase B-Dependent Phosphorylation and Inactivation of WEE1Hu Promote Cell Cycle Progression at G2/M Transition , 2005, Molecular and Cellular Biology.
[52] Jiri Bartek,et al. Targeting the checkpoint kinases: chemosensitization versus chemoprotection , 2004, Nature Reviews Cancer.
[53] E. Sausville,et al. Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin , 2010, Clinical Cancer Research.
[54] Elizabeth Iorns,et al. Integrated Functional, Gene Expression and Genomic Analysis for the Identification of Cancer Targets , 2009, PloS one.
[55] C. Britten,et al. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer , 2008, British Journal of Cancer.
[56] Paul Nurse,et al. Genetic control of cell size at cell division in yeast , 1975, Nature.
[57] L. Schwartz,et al. A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma , 2006, Investigational New Drugs.
[58] H. Koga,et al. Inhibition of proteasome‐dependent degradation of Wee1 in G2‐arrested Hep3B cells by TGFβ1 , 2003, Molecular carcinogenesis.
[59] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[60] J. Wolchok,et al. Phase II Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Metastatic Melanoma , 2008, Clinical Cancer Research.
[61] M. Igarashi,et al. Wee1 +-like gene in human cells , 1991, Nature.
[62] A. Oza,et al. A phase I pharmacological and pharmacodynamic study of MK-1775, a Wee1 tyrosine kinase inhibitor, in monotherapy and combination with gemcitabine, cisplatin, or carboplatin in patients with advanced solid tumors. , 2010 .
[63] N Watanabe,et al. Regulation of the human WEE1Hu CDK tyrosine 15‐kinase during the cell cycle. , 1995, The EMBO journal.
[64] R. Medema,et al. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. , 2004, Molecular cell.
[65] C. Deng,et al. Murine Wee1 Plays a Critical Role in Cell Cycle Regulation and Pre-Implantation Stages of Embryonic Development , 2006, International journal of biological sciences.
[66] H. Dixon,et al. Therapeutic Exploitation of Checkpoint Defects in Cancer Cells Lacking p53 Function , 2002, Cell cycle.
[67] F. Sarkar,et al. A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. , 2005, Clinical prostate cancer.
[68] M. Fallahi,et al. Redundant Ubiquitin Ligase Activities Regulate Wee1 Degradation and Mitotic Entry , 2007, Cell cycle.
[69] H. Yoshida,et al. Akt inhibits Myt1 in the signalling pathway that leads to meiotic G2/M-phase transition , 2002, Nature Cell Biology.
[70] H. Piwnica-Worms,et al. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. , 1992, Science.
[71] C. Erlichman. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90 , 2009, Expert opinion on investigational drugs.
[72] N. Caplen,et al. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome , 2010, Breast Cancer Research and Treatment.
[73] Yi Sun,et al. Binding of 14-3-3 b to the Carboxyl Terminus of Wee 1 Increases Wee 1 Stability , Kinase Activity , and G 2M Cell Population , 2000 .
[74] M. Ernstoff,et al. Modulation of Cell Cycle Progression in Human Tumors: A Pharmacokinetic and Tumor Molecular Pharmacodynamic Study of Cisplatin Plus the Chk1 Inhibitor UCN-01 (NSC 638850) , 2006, Clinical Cancer Research.
[75] S. Taviaux,et al. Localization of human cell cycle regulatory genes CDC25C to 5q31 and WEE1 to 11p15.3-11p15.1 by fluorescence in situ hybridization. , 1993, Genomics.
[76] Mark W. Dewhirst,et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.
[77] Bernard Ducommun,et al. CDC25 phosphatases in cancer cells: key players? Good targets? , 2007, Nature Reviews Cancer.
[78] W. Hait,et al. Reversal of Stathmin-Mediated Resistance to Paclitaxel and Vinblastine in Human Breast Carcinoma Cells , 2007, Molecular Pharmacology.
[79] James E. Ferrell,et al. Substrate Competition as a Source of Ultrasensitivity in the Inactivation of Wee1 , 2007, Cell.
[80] Philip C. De Witt Hamer,et al. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies , 2010 .
[81] J. Ruderman,et al. Changes in regulatory phosphorylation of Cdc25C Ser287 and Wee1 Ser549 during normal cell cycle progression and checkpoint arrests. , 2005, Molecular biology of the cell.
[82] Hiroyuki Osada,et al. M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[83] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[84] W. Denny,et al. Synthesis and structure-activity relationships of soluble 8-substituted 4-(2-chlorophenyl)-9-hydroxypyrrolo[3,4-c]carbazole-1,3(2H,6H)-diones as inhibitors of the Wee1 and Chk1 checkpoint kinases. , 2008, Bioorganic & medicinal chemistry letters.
[85] T. Kawabe. G2 checkpoint abrogators as anticancer drugs. , 2004, Molecular cancer therapeutics.